RBC Reaffirms Buy Rating on AstraZeneca with £145 Price Target
RBC Capital analyst Trung Huynh has reaffirmed his Buy rating on AstraZeneca, setting a price target of £145.00.
According to TipRanks, Huynh is a highly regarded analyst with an average return of 22.7% and a success rate of 75.69%. He covers the Healthcare sector, focusing on stocks like Bristol-Myers Squibb, Merck & Company, and Pfizer.
AstraZeneca's latest earnings release for the quarter ending June 30 showed a quarterly revenue of £15.29 billion and a net profit of £2.49 billion, compared to last year's revenue of £14.84 billion and net profit of £2.52 billion.
Notably, this is not the only positive view on AstraZeneca; Barclays's James Gordon CFA also has a Buy rating on the company. However, Deutsche Bank maintains a Sell rating, presenting a mixed picture for investors.